Climate Change Data

Medeon Biodesign, Inc.

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:154,171 kg/year (2022)

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Reduced carbon emissions (though increased from 73,411 kg in 2021 to 154,171 kg in 2022 due to FDA inspections and cleanroom requirements)

Social Achievements

  • Maintained harmonious labor relations with no labor disputes; 36 participants in human rights education training; 20 employees had health checkups and 48 received influenza vaccinations; no occupational injuries, diseases, or fatalities; implemented various employee welfare measures, training, and retirement systems; average annual salary adjustment of 5.2% in 2022; 56% female employees and 63% female supervisors.
  • Community investment: Donations to Citizenship Class on the Road and Crazy Cat Charity Association

Governance Achievements

  • Established an Audit Committee and a Remuneration Committee; implemented a Board of Directors diversity policy; appointed a Chief Corporate Governance Officer; established ethical corporate management policies and programs; implemented a risk management framework for information and communications security; established information security policies and specific management plans; conducted information security education and training; established a whistle-blowing channel.

Climate Goals & Targets

Long-term Goals:
  • Achieve long-term and stable positive cash flow through development and licensing of innovative medical devices and CDMO business
Short-term Goals:
  • Assist Terumo in obtaining PMA market approval for Cross-Seal™ and obtain milestone payments for 1B, 2A-2, and 3A; continue enrollment and follow-up work for Urocross™; continue preparation and application work for CVS-T01 clinical study in the US; broaden Medeologix's customer base; increase mass production capacity in Taiwan; recruit advanced manufacturing talents; conduct technological upgrading.

Environmental Challenges

  • High research and development costs and time for advanced medical devices; need to develop products to a more mature stage for licensing or partnerships; establishment of domestic advanced medical device value chain and talent pool; less developed upstream and downstream resources in Taiwan compared to developed countries.
  • Increased carbon emissions in 2022 due to FDA inspections and cleanroom requirements
Mitigation Strategies
  • Careful selection of R&D projects; collaboration with international manufacturers; experience in product development and manufacturing expense control; enhanced efficiency of resource utilization; cultivation of local engineering and medical integration talents; establishment of a successful model of advanced medical device development with fully localized R&D, manufacturing, and regulatory certification; expansion of global network of top industry and medical connections; pursuing medical device contract development and manufacturing markets; integrating CDMO capacity and customer base to create a complete global supply system with upstream and downstream integration; implementing energy-saving measures in offices and laboratories.

Supply Chain Management

Supplier Audits: 1 supplier re-evaluation (2022)

Climate-Related Risks & Opportunities

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:132,838 kg/year

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Reduced carbon emissions by 5% in 2023 compared to 2022 (132,838 kg vs 160,286 kg)

Social Achievements

  • Implemented various employee welfare measures, including group insurance, annual vacations exceeding legal requirements, employee stock options, subsidies, and travel benefits.
  • Maintained harmonious labor relations with no disputes requiring agreements.
  • Female employees comprised 62.5% of the workforce, exceeding the 2023 target of 40% or above.
  • Female managerial officers made up 67% of all managerial positions, exceeding the 2023 target of 40% or above.

Governance Achievements

  • Established an Audit Committee and a Remuneration Committee.
  • Implemented a Board of Directors diversity policy.
  • Maintained a high attendance rate at Board and Audit Committee meetings.
  • Established an information security policy and implemented various security measures.

Climate Goals & Targets

Long-term Goals:
  • Achieve long-term and stable positive cash flow through innovative medical device development and licensing, and CDMO business.
Short-term Goals:
  • Assist Terumo in obtaining Supplement PMA for the next-generation Cross-Seal product and launch it to market.
  • Advance clinical trials for Urocross and Duett products.
  • Expand CDMO services and improve production efficiency.
  • Strengthen R&D capabilities and cultivate domestic talents.

Environmental Challenges

  • High research and development costs and time for advanced medical devices.
  • Need to develop products to a more mature stage to increase licensing or partnership opportunities.
  • Challenges in establishing a fully localized R&D, manufacturing, and regulatory certification model for advanced medical devices in Taiwan.
  • Well-developed upstream and downstream resources in developed countries compared to Taiwan.
Mitigation Strategies
  • Careful selection of R&D projects with high market value.
  • Collaboration with international manufacturers to control development and manufacturing expenses.
  • Cultivating local engineering and medical integration talents.
  • Expanding global network of industry and medical connections.
  • Integrating CDMO capacity and customer base to create a complete global supply system.

Supply Chain Management

Climate-Related Risks & Opportunities

UN Sustainable Development Goals

  • SDG 3
  • SDG 8
  • SDG 10

Supporting organizations that promote inclusive workplaces and equal employment opportunities for people with disabilities.